Global Antibacterial Drugs Market, by Drug class (Beta lactams, Quinolones, Macrolides, Tetracycline, Aminoglycoside, Sulfonamide, Phenicols, and Others), by Route of Administration (Oral, Topical, Parenteral, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 43,791.2 million in 2017, and is projected to exhibit a CAGR of 1.4% over the forecast period (2018 – 2026). Increasing research and development by market players to augment the market growth Key players in the market are focused on research and development in order to develop novel products to address the critical unmet needs of patients. For instance, in September 2018, the Pew Charitable Trusts reviewed the antibacterial agents in clinical development phase and they found around 42 antibacterial agents, which are under pipeline. Out of these, around 15 were in Phase 1 and Phase 12, around 11 were in Phase 2, around 11 were in phase 3, and 4 have been submitted to the national medicines authority. Moreover, Relebactam + Imipenem/Cilastatin MK-7655A developed by Merck & Co., Inc., is under Phase 3 clinical trial indicated for treatment of Urinary Tract Infection. Increase in antibacterial resistance, is expected to increase the research and development for innovative and novel antibacterial drugs, which in turn is expected to boost the market growth. In 2015, the World Health Organization (WHO) planned a preventive measure called as ‘Global Action Plan on Antimicrobial Resistance’, such initiatives are expected to get maximum benefits of drug in long term and launch of new drugs for better healthcare.
Browse 25 Market Data Tables and 27 Figures spread through 156 Pages and in-depth TOC on ‘Antibacterial Drugs Market’- Global Forecast to 2026, by Drug class (Beta lactams, Quinolones, Macrolides, Tetracycline, Aminoglycoside, Sulfonamide, Phenicols, and Others), by Route of Administration (Oral, Topical, Parenteral, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the antibacterial drugs market, click the link below:
Key players in the market are focused on adopting strategies such as mergers and acquisitions to enhance their product portfolio. For instance, in January 2018, Melinta Therapeutics, Inc., announced the acquisition of The Medicines Company’s infectious disease business, this acquisition is expected to strengthen the Melinta’s infectious disease product portfolio and position it to be the leading antibiotics company.
Key Takeaways of the Antibacterial Drugs Market:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.